On April 27, 2026 Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), reported that its Chief Medical Officer, Dr. Carman Giacomantonio presented data from its first-in-human early feasibility study for its Targeted Hyperthermia Therapy cancer treatment at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) ("AACR") last week in San Diego. Dr. Giacomantonio has also been accepted to present Sona’s data at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) ("ASCO") annual meeting May 29 – June 2, 2026, a conference centered on scientific innovation and its translation into practical patient-centered clinical application.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Giacomantonio commented, "AACR is the premier stage for sharing breakthrough science, and it was exciting to see our Targeted Hyperthermia Therapy align so well with the conference’s focus on overcoming immunotherapy resistance. The feedback we received on our clinical study was incredibly encouraging and confirms for us that we’re on the right path toward offering new hope to patients who have run out of options. Next, we are delighted to have been invited to share our compelling data to the more industry-focused ASCO (Free ASCO Whitepaper) conference."
The presentation highlights the initial safety, tolerability and anti-tumor activity from this study which demonstrated a complete response in treated indicative tumors in six out of ten late-stage melanoma patients who had previously failed on standard of care immunotherapy. This study is a critical milestone in the Company’s mission to treat immunotherapy-resistant solid tumors in humans. A manuscript detailing these results is currently being prepared for submission to a leading peer-reviewed scientific journal.
Sona’s first-in-human study results speak to a persistent unmet need that remains the dominant conversation in the melanoma community. The Melanoma Research Alliance noted in October 2025 that roughly half of advanced melanoma patients still do not respond to — or develop resistance to — currently approved immunotherapies. Sona’s study was conducted in patients from precisely this refractory group.
Next month’s ASCO (Free ASCO Whitepaper) annual meeting is the world’s most significant gathering of oncology professionals, serving as the premier global stage for the unveiling of practice-changing clinical research. Each year, more than 40,000 oncology experts, patient advocates, and industry leaders from over 150 countries convene to present and discuss the latest advances in clinical cancer care. Known for its focus on the "bench-to-bedside" transition, the meeting features groundbreaking abstracts and clinical trial results that directly influence the standard of care for patients worldwide.
(Press release, Sona Nanotech, APR 27, 2026, View Source [SID1234664805])